Objective: It is estimated that circa 50,000 individuals have relapsing-remitting multiple sclerosis in Latin America. European and NorthAmerican algorithms for the treatment of multiple sclerosis do not foresee our regional difficulties and the access of patients to treatment. Methods: The Latin American Multiple Sclerosis Forum is an independent and supra-institutional group of experts that has assessed the latest scientific evidence regarding efficacy and safety of disease-modifying treatments. Accesses to treatment and pharmacovigilance programs for each of the eight countries represented at the Forum were also analyzed. Results: A specific set of guidelines based upon evidence-based recommendations was designed for Latin America. Futur...
A very high prevalence of multiple sclerosis (MS) has been reported in some Western European and Nor...
ABSTRACT Multiple sclerosis has become an ever-increasing challenge to neurologists. With the releas...
With the advent of new disease-modifying drugs, the treatment of multiple sclerosis is becoming incr...
OBJECTIVE: It is estimated that circa 50,000 individuals have relapsing-remitting multiple sclerosis...
Objective : The prevalence of multiple sclerosis (MS) in Latin America varies across different studi...
Objective: The prevalence of multiple sclerosis (MS) in Latin America varies across different studie...
Introduction. Considerable progress has been made in the treatment of patients with relapsing-remitt...
Introduction. Multiple sclerosis (MS) is the most common primary demyelinating disease affecting the...
OBJECTIVE: It is estimated that circa 50,000 individuals have relapsing-remitting multiple sclerosis...
Before the advent of diagnostic criteria for multiple sclerosis (MS), it was reported that the preva...
Before the advent of diagnostic criteria for multiple sclerosis (MS), it was reported that the preva...
The Latin American MS Experts' Forum has developed practical recommendations on the initiation and o...
Limited data suggest that multiple sclerosis (MS) in Latin America (LA) could be less severe than in...
ABSTRACT The expanding therapeutic arsenal in multiple sclerosis (MS) has allowed for more effective...
Artículo de publicación ISIA very high prevalence of multiple sclerosis (MS) has been reported in so...
A very high prevalence of multiple sclerosis (MS) has been reported in some Western European and Nor...
ABSTRACT Multiple sclerosis has become an ever-increasing challenge to neurologists. With the releas...
With the advent of new disease-modifying drugs, the treatment of multiple sclerosis is becoming incr...
OBJECTIVE: It is estimated that circa 50,000 individuals have relapsing-remitting multiple sclerosis...
Objective : The prevalence of multiple sclerosis (MS) in Latin America varies across different studi...
Objective: The prevalence of multiple sclerosis (MS) in Latin America varies across different studie...
Introduction. Considerable progress has been made in the treatment of patients with relapsing-remitt...
Introduction. Multiple sclerosis (MS) is the most common primary demyelinating disease affecting the...
OBJECTIVE: It is estimated that circa 50,000 individuals have relapsing-remitting multiple sclerosis...
Before the advent of diagnostic criteria for multiple sclerosis (MS), it was reported that the preva...
Before the advent of diagnostic criteria for multiple sclerosis (MS), it was reported that the preva...
The Latin American MS Experts' Forum has developed practical recommendations on the initiation and o...
Limited data suggest that multiple sclerosis (MS) in Latin America (LA) could be less severe than in...
ABSTRACT The expanding therapeutic arsenal in multiple sclerosis (MS) has allowed for more effective...
Artículo de publicación ISIA very high prevalence of multiple sclerosis (MS) has been reported in so...
A very high prevalence of multiple sclerosis (MS) has been reported in some Western European and Nor...
ABSTRACT Multiple sclerosis has become an ever-increasing challenge to neurologists. With the releas...
With the advent of new disease-modifying drugs, the treatment of multiple sclerosis is becoming incr...